Mingwei Fei

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

Christopher S. Hourigan, Laura W. Dillon, Gege Gui et al. · Journal of Clinical Oncology · 2019 · 428 citations · Full text

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser et al. · The Lancet Haematology · 2019 · 274 citations

Versus Tacrolimus, Transplantation, Immunosuppressive Therapy +9

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

Bart L. Scott, Marcelo C. Pasquini, Mingwei Fei et al. · Transplantation and Cellular Therapy · 2021 · 136 citations · Full text

Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

Parameswaran Hari, Marcelo C. Pasquini, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2020 · 101 citations

Cell Therapy, Disease Progression, Prognosis +20

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

Jeffrey Schriber, Parameswaran Hari, Kwang Woo Ahn et al. · Cancer · 2017 · 86 citations · Full text